PulmoTech

PulmoTech BV operates within the therapeutic devices sector of the HealthTech industry, specializing in solutions for critically ill, mechanically ventilated patients. The company was established in 2018 by founder Rutger Flink in Groningen, the Netherlands.

The core of PulmoTech's offering is its Intelligent Esophageal Pressure System (iEPS). This system is an advanced esophageal pressure catheter designed to guide mechanical ventilation. It features a small tube with specialized sensors that is inserted through the nose or mouth into the esophagus. This placement allows for the accurate measurement of respiratory muscle function and lung function, providing critical data to intensivists. By integrating esophageal pressure measurement directly with a nasogastric feeding catheter, the device offers a more comprehensive approach to patient monitoring without requiring additional invasive procedures.

The company's journey includes several key milestones. In October 2019, it secured an investment from Carduso Capital, which was pivotal for advancing the development of its esophageal catheter. Subsequently, PulmoTech earned both ISO 13485 certification and a CE mark under the Medical Device Regulation (MDR) for its system, validating its quality and safety standards for the European market. Demonstrating its strategic value in the market, PulmoTech BV was acquired by Sentec on March 27, 2025, and now functions as an operating subsidiary.

Keywords: esophageal pressure monitoring, mechanical ventilation, therapeutic devices, critical care, respiratory monitoring, HealthTech, medical devices, intensive care unit, esophageal catheter, patient monitoring, nasogastric feeding, lung function measurement, respiratory muscle function, ventilator management, CE mark medical device, ISO 13485, Sentec acquisition